EADV 2025 News: New Brivekimig Data Supports Targeting TNF and OX40L in HS

September 17, 2025

EADV 2025 Coverage: Incyte’s Povorcitinib Improves Moderate-to-severe HS at Week 24

September 17, 2025

HS Research Brief: Bimekizumab (Bimzelx, UCB) Provides Sustained Symptom Relief for up to 3 Years

September 17, 2025

Incyte Launches HS TRUTHS Campaign

September 3, 2025

Four Expert Strategies That Will Enhance HS Management

September 2, 2025

Key Takeaways From the Second Annual UCB HS Summit With Dr. Steve Daveluy

August 14, 2025

UCB Expands “Get Yourself Back” DTC Campaign for HS Community

July 8, 2025

HS Pipeline Watch: Zura Bio Launches Global Phase 2 Study of Its Dual IL-17A and BAFF Inhibitor in Adults With HS

May 20, 2025

2025 SID Annual Meeting Coverage: Mayo Clinic Insights on Biologics and Patient Outcomes in HS

May 9, 2025

HS Connect Launches “The Healing Space,” A Mental Health Hub for HS Patients

May 2, 2025

Awareness Gap: Many HS Patients Don’t Know About New Treatment Options

April 1, 2025

Incyte’s Povorcitinib Hits Primary Endpoints in Phase 3 HS Studies

March 17, 2025